The next focusIR Investor Webinar takes place tomorrow with guest speakers from WS Blue Whale Growth Fund, Taseko Mines, Kavango Resources and CQS Natural Resources fund. Please register here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksPureTech Share News (PRTC)

Share Price Information for PureTech (PRTC)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 223.00
Bid: 221.50
Ask: 223.50
Change: 1.00 (0.45%)
Spread: 2.00 (0.903%)
Open: 220.50
High: 223.50
Low: 218.00
Prev. Close: 222.00
PRTC Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

LONDON BRIEFING: UK retail sales fall; AstraZeneca gets US approval

Fri, 17th Nov 2023 07:58

(Alliance News) - Stock prices in London are still set to open higher on Friday, despite October retail sales figures for the UK disappointing shortly before the opening bell.

UK retail sales declined last month despite expectations of a month-on-month increase, and declined faster than expected on an annual basis, official numbers on Friday showed.

"Cost of living pressures, reduced footfall and the great British weather all played their part. There are signs that cracks are starting to appear in the economy with consumers tightening their belts and switching to cheaper brands. Consumers are still spending more and getting less with retail sales volumes now at their lowest level since February 2021," said Wealth Club's Charlie Huggins.

Meanwhile, Swissquote Bank analyst Ipek Ozkardeskaya was upbeat ahead of the final day of trading this week, particularly when reflecting upon the week's news coming out of the US.

"This week could hardly be better in terms of economic, political, and geopolitical news. The US inflation slowed more than expected, the US politicians inked a short-term deal to avert a shutdown," said Ozkardeskaya.

"On top, the US retail sales fell last month, but fell less than expected, the initial jobless claims rose, and the US unemployment benefits reached the highest level in almost two years, factory production fell more than expected and homebuilder sentiment fell to the lowest level for the year."

Here is what you need to know at the London market open:

----------

MARKETS

----------

FTSE 100: called up 0.4% at 7,441.17

----------

Hang Seng: down 2.1% at 17,452.71

Nikkei 225: closed up 0.5% at 33,585.20

S&P/ASX 200: closed down 0.1% at 7,049.40

----------

DJIA: closed down 45.74 points, or 0.1%, at 34,945.47

S&P 500: closed up 5.36 points, or 0.1%, at 4,508.24

Nasdaq Composite: closed up 9.84 points, or 0.1%, at 14,113.67

----------

EUR: down at USD1.0839 (USD1.0840)

GBP: down at USD1.2377 (USD1.2398)

USD: down at JPY150.50 (JPY151.34)

Gold: up at USD1,986.42 per ounce (USD1,966.26)

(Brent): down at USD77.41 a barrel (USD80.84)

(changes since previous London equities close)

----------

ECONOMICS

----------

Friday's key economic events still to come:

10:00 CET EU balance of payments

11:00 CET EU CPI

08:30 EST US housing starts

08:30 CST US Fed Chicago President Austan Goolsbee speaks

10:00 EST US advance quarterly services

US FRB Boston President Susan Collins speaks

US Federal Reserve Board Vice Chair Michael Barr speaks

UK BoE Deputy Governor David Ramsden speaks

----------

According to the Office for National Statistics, retail sales volumes declined 2.7% year-on-year in October, quickening from a 1.3% decline in September. The September figure was revised from a previous 1.0% decline. The October read also came in worse than feared, with market expectations of a 1.5% decline, according to FXStreet-cited consensus. Retail sales declined 0.3% in October from September, falling short of consensus. A monthly increase of 0.3% was forecast, according to FXStreet. In September, retail sales had fallen 1.1% from August, revised from a previous 0.9% decline. "Non-food stores sales volumes fell by 0.2% in October 2023, following a 2.1% fall in September 2023; retailers suggested that cost of living, reduced footfall and the wet weather in the second half of the month contributed to the fall," the ONS noted.

----------

US President Joe Biden has signed a temporary spending bill a day before a potential government shutdown. The move pushes a fight with congressional Republicans over the federal budget into the new year, and wartime aid for Ukraine and Israel remains stalled. The measure passed the US house and senate by wide bipartisan margins this week, ensuring the government remains open until after the holiday season. It also potentially giving legislators more time to sort out their considerable differences over government spending levels for the current fiscal year. Biden signed the bill in San Francisco, where he is hosting the summit of Asia-Pacific Economic Co-operation economies.

----------

BROKER RATING CHANGES

----------

Barclays raises NatWest to 'overweight' (equal weight) - price target 330 (315) pence

----------

Barclays raises Babcock International to 'overweight' (equal weight) - price target 529 (325) pence

----------

Jefferies cuts Great Portland Estates to 'underperform' (hold) - price target 352 (387) pence

----------

COMPANIES - FTSE 100

----------

AstraZeneca said its Truqap treatment for patients with advanced hormone receptor positive breast cancer, in combination with Faslodex, has been approved by the US Food & Drug Administration. This follows the results from its CapItello-291 phase 3 trial published earlier this year, which showed reduced risk of disease progression or death by 50% compared to Faslodex alone. AstraZeneca Executive Vice President, Oncology Business Unit Dave Fredrickson commented: "The rapid US approval of Truqap reinforces the important role of the PI3K/AKT pathway in HR-positive breast cancer and the critical need to test patients at the time of diagnosis, as up to fifty per cent have tumours with these alterations. As a first-in-class medicine, this approval provides a critical new option for patients in the US with this specific type of disease and we look forward to bringing Truqap to the many breast cancer patients who can benefit across the globe."

----------

COMPANIES - FTSE 250

----------

PureTech Health said its founded entity Karuna Therapeutics has announced positive results from its phase 1b ambulatory blood pressure monitoring trial of KarXT in treating schizophrenia. The biotechnology firm said results demonstrate that KarXT was not associated with clinically meaningful increases in blood pressure in adults with schizophrenia. This is alongside meeting its primary endpoint of demonstrating a mean change from baseline to week 8 in 24-hour ambulatory systolic blood pressure of negative 0.59 millimetres of mercury. It said KarXT was "generally well tolerated", with a side effect profile consistent with prior trials in the Emergent programme evaluating KarXT in schizophrenia.

----------

OTHER COMPANIES

----------

FRP Advisory said its performance was strong during the half-year that ended October 31. The corporate finance, restructuring and debt adviser said it expects first half revenue of GBP58.7 million, up 19% from GBP49.4 million a year earlier, alongside underlying adjusted earnings before interest, tax, depreciation and amortisation rising 34% to GBP15.5 million from GBP11.6 million. It noted the restructuring having seen an increase in activity levels during calendar 2023, including administrations approaching pre-pandemic levels. The company said: "Companies with significant borrowings who have rolled off lower interest rate arrangements are now subject to much higher debt service costs, with interest rates now considerably higher than the 2009-2021 period...Certain sectors such as construction, property, casual dining and food service, retail, administrative and support services are finding current trading conditions particularly challenging." Chief Executive Officer Geoff Rowley added: "We remain confident of making further progress, with leading positions in our core markets and a team and structure that leaves us well positioned to support corporates through the business cycle and respond to increased demand for our services."

----------

By Greg Rosenvinge, Alliance News senior reporter

Comments and questions to newsroom@alliancenews.com

Copyright 2023 Alliance News Ltd. All Rights Reserved.

More News
21 Jun 2023 12:36

PureTech Health launches next stage of anxiety disorder drug trial

(Alliance News) - PureTech Health PLC on Wednesday said that it has started the next stage of trials for LYT-300, in order to test whether the therapy could be used to treat anxiety disorders.

Read more
7 Jun 2023 13:57

PureTech Health's Akili launches ADHD immersive treatment in US

(Alliance News) - PureTech Health PLC on Wednesday said its founded entity, Akili Inc, released an attention deficit hyperactivity disorder treatment for adult patients.

Read more
9 May 2023 11:13

PureTech's Vedanta Biosciences receives US FDA fast track designation

(Alliance News) - PureTech Health PLC on Tuesday said its founded entity, Vedanta Biosciences, has been granted fast track designation from the US Food & Drug Administration for its bacterial consortium candidate, VE303, for the prevention of recurrent Clostridioides difficile infection.

Read more
4 May 2023 11:46

IN BRIEF: PureTech notes Akili's results for EndeavorRx ADHD trial

PureTech Health PLC - Boston-based biotechnology company - Says its founded entity, Akili, announced clinical trial for video game-based therapy, EndeavorRx, showed improvement in attention and quality of life for people with attention deficit hyperactivity disorder. Notes attention improved in more than 80% of adults with ADHD, while over a third of participants "no longer exhibited an attention deficit following treatment."

Read more
2 May 2023 09:34

LONDON BROKER RATINGS: HSBC raises Rightmove to 'buy' from 'hold'

(Alliance News) - The following London-listed shares received analyst recommendations Tuesday morning:

Read more
28 Apr 2023 11:13

PureTech Health yearly loss widens but remains optimistic

(Alliance News) - PureTech Health PLC on Friday said its loss widened in 2022 and revenue declined, though it hailed an "exceptional" year and expects further success in 2023.

Read more
25 Apr 2023 18:33

TRADING UPDATES: Eagle Eye signs new John Lewis deal, Neometals update

(Alliance News) - The following is a round-up of updates by London-listed companies, issued on xxxday and not separately reported by Alliance News:

Read more
21 Apr 2023 15:51

UK earnings, trading statements calendar - next 7 days

Monday 24 April 
Brighton Pier Group PLCFull Year Results
CentralNic Group PLCTrading Statement
Checkit PLCFull Year Results
Egdon Resources PLCHalf Year Results
Keystone Law Group PLCFull Year Results
Lok'n Store Group PLCHalf Year Results
Novacyt SAFull Year Results
Tuesday 25 April 
AB Dynamics PLCHalf Year Results
Anglo American PLCTrading Statement
Associated British Foods PLCHalf Year Results
Avacta Group PLCFull Year Results
Banco Santander SAQ1 Results
Card Factory PLCFull Year Results
Coca-Cola Europacific Partners PLCTrading Statement
Corero Network Security PLCFull Year Results
Dillistone Group PLCFull Year Results
Focusrite PLCHalf Year Results
hVIVO PLCFull Year Results
IWG PLCTrading Statement
Jadestone Energy PLCFull Year Results
Loungers PLCTrading Statement
Next Fifteen Communications Group PLCFull Year Results
Northcoders Group PLCFull Year Results
Oxford BioMedica PLCFull Year Results
Quilter PLCTrading Statement
Resolute Mining LtdTrading Statement
Round Hill Music Royalty Fund LtdFull Year Results
RWS Holdings PLCTrading Statement
Travis Perkins PLCTrading Statement
WAG Payment Solutions PLCTrading Statement
Whitbread PLCFull Year Results
Wednesday 26 April 
1Spatial PLCFull Year Results
Biome Technologies PLCFull Year Results
Bunzl PLCQ1 Results
C4X Discovery Holdings PLCHalf Year Results
CRH PLCTrading Statement
Ecora Resources PLCTrading Statement
Frenkel Topping Group PLCFull Year Results
Fresnillo PLCTrading Statement
Gem Diamonds LtdTrading Statement
Glencore PLCTrading Statement
GSK PLCQ1 Results
Home REIT PLCHalf Year Results
Learning Technologies Group PLCFull Year Results
Man Group PLCTrading Statement
Pennant International Group PLCFull Year Results
RBG Holdings PLCFull Year Results
Reckitt Benckiser Group PLCTrading Statement
Sanderson Design Group PLCFull Year Results
Skillcast Group PLCFull Year Results
Smith & Nephew PLCTrading Statement
Standard Chartered PLCQ1 Results
Trifast PLCTrading Statement
Warpaint London PLCFull Year Results
Thursday 27 April 
AstraZeneca PLCTrading Statement
Barclays PLCQ1 Results
Brave Bison Group PLCFull Year Results
Capricorn Energy PLCFull Year Results
GCP Infrastructure Investments LtdTrading Statement
Howden Joinery Group PLCTrading Statement
Inchcape PLCTrading Statement
Indivior PLCQ1 Results
Inspecs Group PLCFull Year Results
J Sainsbury PLCFull Year Results
Lancashire Holdings LtdTrading Statement
Literacy Capital PLCTrading Statement
London Stock Exchange Group PLCTrading Statement
Molten Ventures PLCTrading Statement
Petrofac LtdFull Year Results
PPHE Hotel Group LtdTrading Statement
Schroders PLCTrading Statement
Spectris PLCQ1 Results
St James's Place PLCTrading Statement
Synairgen PLCFull Year Results
Taylor Wimpey PLCTrading Statement
Unilever PLCTrading Statement
WPP PLCTrading Statement
Friday 28 April 
Alphawave IP Group PLCFull Year Results
Alphawave IP Group PLCTrading Statement
Argo Blockchain PLCfull Year Results
Computacenter PLCTrading Statement
Hikma Pharmaceuticals PLCTrading Statement
Industrials REIT LtdTrading Statement
James Fisher & Sons PLCFull Year Results
Kingspan Group PLCTrading Statement
LMS Capital PLCTrading Statement
Morgan Advanced Materials PLCFull Year Results
NatWest Group PLCQ1 Results
Pearson PLCTrading Statement
PureTech Health PLCFull Year Results
Record PLCTrading Statement
Renishaw PLCTrading Statement
Rotork PLCQ1 Results
Smurfit Kappa Group PLCTrading Statement
Westminster Group PLCFull Year Results
  
Copyright 2023 Alliance News Ltd. All Rights Reserved.

Read more
17 Apr 2023 09:01

PureTech Health's Vedanta Biosciences boasts "promising" results

(Alliance News) - PureTech Health PLC on Monday said that its founded entity, Vedanta Biosciences, has seen positive results for its lead programme, VE303.

Read more
23 Mar 2023 12:23

LONDON MARKET MIDDAY: Bank of England lifts rates by 25 basis points

(Alliance News) - Stock prices in London were largely lower at midday on Thursday, raised UK interest rates by 25 basis points on Thursday, as widely expected, and indicated that further tightening in monetary policy may be required.

Read more
23 Mar 2023 10:11

PureTech Health says Royalty Pharma acquires Karuna Royalties

(Alliance News) - PureTech Health PLC on Thursday said Royalty Pharma PLC has acquired an interest in PureTech's royalty in Karuna Therapeutics Inc's KarXT schizophrenia treatment.

Read more
23 Mar 2023 07:24

US Royalty Pharma strikes deal with PureTech Health on KarXT royalties

(Sharecast News) - US-listed Royalty Pharma has acquired an interest in PureTech Health's royalty in Karuna Therapeutics' KarXT drug for up to $500m, with $100m in cash up front and up to $400m in additional payments contingent on the achievement of certain regulatory and commercial milestones.

Read more
20 Mar 2023 16:01

PureTech Health says Karuna KArXT trial receives positive results

(Alliance News) - PureTech Health PLC on Monday said its founded entity, Karuna Therapeutics Inc announced its phase 3 EMERGENT-3 trial of KarXT in Schizophrenia has met its primary endpoint.

Read more
28 Feb 2023 21:05

TRADING UPDATES: Eco Atlantic swings to loss; Curtis approves takeover

(Alliance News) - The following is a round-up of updates by London-listed companies, issued on Monday and not separately reported by Alliance News:

Read more
14 Feb 2023 13:27

IN BRIEF: PureTech Health to start trials for anxiety, depression drug

PureTech Health PLC - clinical-stage biotherapeutics company - Says it will advance LYT-300 for the potential treatment of anxiety disorders and post-partum depression. A placebo-controlled, phase 2a, proof-of-concept, social anxiety clinical trial is expected to begin in the first half of 2023. Results are expected by the end of the year. An open-label, phase 2a, proof-of-concept clinical trial in women with post-partum depression is expected to begin in the second half of 2023.

Read more

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.